{"id":"transdermal-scopolamine","safety":{"commonSideEffects":[{"rate":"~50%","effect":"Dry mouth"},{"rate":"~15%","effect":"Drowsiness"},{"rate":"~10%","effect":"Blurred vision"},{"rate":"~5%","effect":"Dizziness"},{"rate":null,"effect":"Mydriasis (dilated pupils)"},{"rate":null,"effect":"Urinary retention"}]},"_chembl":null,"_dailymed":{"setId":"cb93bfad-3e37-4a27-92f6-f21703ae7bdf","title":"SCOPOLAMINE TRANSDERMAL SYSTEM PATCH, EXTENDED RELEASE [PADAGIS ISRAEL PHARMACEUTICALS LTD]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Scopolamine is an anticholinergic agent that crosses the blood-brain barrier and antagonizes M1 muscarinic receptors in the chemoreceptor trigger zone and vestibular nuclei. By suppressing these cholinergic pathways, it prevents the neural signals that trigger nausea and vomiting. The transdermal formulation provides sustained delivery over several days, making it particularly effective for prevention of motion sickness during travel.","oneSentence":"Transdermal scopolamine blocks muscarinic acetylcholine receptors to reduce motion sickness and nausea by decreasing vestibular sensitivity and gastric motility.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:48.258Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of motion sickness"},{"name":"Prevention of nausea and vomiting associated with travel"}]},"trialDetails":[{"nctId":"NCT04366518","phase":"EARLY_PHASE1","title":"Toward a Computationally-Informed, Personalized Treatment for Hallucinations","status":"RECRUITING","sponsor":"Yale University","startDate":"2021-07-15","conditions":"Hallucinations, Auditory, Psychosis","enrollment":35},{"nctId":"NCT02202369","phase":"PHASE4","title":"Multimodal Analgesia vs. Routine Care Pain Management for Lumbar Spine Fusion Surgery: A Prospective Randomized Study","status":"SUSPENDED","sponsor":"OrthoCarolina Research Institute, Inc.","startDate":"2015-06-25","conditions":"Single Level Lumbar Decompression and Fusion Spine Surgery","enrollment":50},{"nctId":"NCT05021263","phase":"PHASE3","title":"Does IV Magnesium Improve Quality of Recovery With ERAS Protocols in Laparoscopic Colorectal Surgery?","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2022-05-27","conditions":"Colo-rectal Cancer, Anesthesia","enrollment":90},{"nctId":"NCT03435003","phase":"PHASE4","title":"Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2017-08-28","conditions":"Post-operative Nausea and Vomiting, Laparoscopic Sleeve Gastrectomy","enrollment":83},{"nctId":"NCT04008264","phase":"","title":"A Novel Usage of Transdermal Scopolamine in Reducing Narcotic Usage in Outpatient Hand Surgery","status":"COMPLETED","sponsor":"Alexander M Spiess, MD","startDate":"2019-06-25","conditions":"Post Operative Pain Management","enrollment":74},{"nctId":"NCT04272255","phase":"PHASE3","title":"Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness","status":"UNKNOWN","sponsor":"Repurposed Therapeutics, Inc.","startDate":"2019-04-22","conditions":"Motion Sickness","enrollment":300},{"nctId":"NCT04184115","phase":"PHASE3","title":"Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness","status":"COMPLETED","sponsor":"Repurposed Therapeutics, Inc.","startDate":"2019-06-09","conditions":"Motion Sickness","enrollment":102},{"nctId":"NCT03920644","phase":"PHASE3","title":"Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels","status":"UNKNOWN","sponsor":"Naval Aeromedical Research Unit, Dayton","startDate":"2019-04","conditions":"Prevention of Nausea Associated With Motion Sickness, Treatment of Nausea Associated With Motion Sickness","enrollment":320},{"nctId":"NCT02839135","phase":"PHASE1","title":"A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-05-13","conditions":"Motion Sickness","enrollment":128},{"nctId":"NCT02410460","phase":"NA","title":"Anesthetics in Rhytidoplasty - A Comparison Study","status":"COMPLETED","sponsor":"Mercy Facial Plastic Surgery Center","startDate":"2013-09","conditions":"Rhytidoplasty","enrollment":30},{"nctId":"NCT01592708","phase":"NA","title":"Study of Anesthesia Techniques to Reduce Nausea and Vomiting After Jaw Corrective Surgery","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2012-06","conditions":"Post-operative Nausea, Post-operative Vomiting, Nausea Persistent","enrollment":233},{"nctId":"NCT00717054","phase":"NA","title":"Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting","status":"COMPLETED","sponsor":"Drexel University","startDate":"2008-02","conditions":"Nausea, Vomiting","enrollment":115},{"nctId":"NCT00659737","phase":"NA","title":"Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting","status":"COMPLETED","sponsor":"Drexel University College of Medicine","startDate":"2008-04","conditions":"Nausea, Vomiting","enrollment":115},{"nctId":"NCT00374478","phase":"PHASE2","title":"Effects of Transdermal Scopolamine on Occupational Performance","status":"COMPLETED","sponsor":"Boston University","startDate":"2005-04","conditions":"Motion Sickness","enrollment":33}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"DIZZINESS"},{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"DISEASE PROGRESSION"},{"count":1,"reaction":"DRUG INEFFECTIVE"},{"count":1,"reaction":"DRUG WITHDRAWAL SYNDROME"},{"count":1,"reaction":"DYSSTASIA"},{"count":1,"reaction":"HEADACHE"},{"count":1,"reaction":"INCORRECT PRODUCT ADMINISTRATION DURATION"},{"count":1,"reaction":"LARGE INTESTINAL OBSTRUCTION"},{"count":1,"reaction":"LETHARGY"}],"_approvalHistory":[],"publicationCount":234,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Transdermal Scopolamine","genericName":"Transdermal Scopolamine","companyName":"Repurposed Therapeutics, Inc.","companyId":"repurposed-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Transdermal scopolamine blocks muscarinic acetylcholine receptors to reduce motion sickness and nausea by decreasing vestibular sensitivity and gastric motility. Used for Prevention of motion sickness, Prevention of nausea and vomiting associated with travel.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}